AB1025 HARMONIZING JAPANESE VERSION OF THE CHILDHOOD HEALTH ASSESSMENT QUESTIONNAIRE (CHAQ) WITH CHAQ
Authors: Takako Miyamae, Yumi Tani, Takayuki Kishi, Hisashi Yamanaka, Gurkirpal Singh
Journal: Annals of the Rheumatic Diseases (2019)

<h3>Background</h3> Juvenile idiopathic arthritis (JIA) is one of the most common rheumatic diseases of childhood. The Childhood Health Assessment Questionnaire (CHAQ) is one of the most widely-used self-report questionnaires to measure patient disability and discomfort (1). The American English version of the CHAQ was previously translated into Japanese, cross-culturally adapted and validated in a cohort of healthy Japanese children and Japanese patients with JIA (2). <h3>Objectives</h3> To revise the Japanese version of the CHAQ (JCAHQ) to meet requirements of clinical international trials that pool data from various centers in different countries which need the same number of questions in each functional area of the CHAQ and to validate the harmonized JCHAQ with JIA patients. <h3>Methods</h3> The questionnaire in the JCHAQ consisted of 36 items, measuring eight functional areas: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and activities, was changed to 30 items of questionnaire as each functional area has same number of questions as the original American English version after a conference among pediatric rheumatologists in US and Japan. The revised version was professionally translated from English to Japanese and reviewed by the rheumatologists for accuracy. Then, it was validated with Japanese JIA patients. <h3>Results</h3> A total of 42 JIA patients were enrolled in the validation: 7 systemic, 30 polyarticular/oligoarticular and 5 enthesis related. Most patients were well controlled and the median disability index (DI) scores was 0.0, however, significant correlation was seen with VAS (Visual Analog Scale) of pain, VAS overall well-being, physician VAS, DAS (Disease Activity Score)28-ESR, and JADAS (Juvenile Arthritis Disease Activity Score)-27. All variables in the questionnaire were shown to be significant (P&lt;0.001). In comparison of two groups of disease activity, remission/mild vs. moderate/severe, both DAS28-ESR and JADAS27 showed significant correlation with DI. <h3>Conclusion</h3> The Harmonized JCHAQ was a reliable and valid tool for the functional assessment of children with JIA. It is more suitable for international comparison. <h3>References</h3> [1] Singh G, et al. Measurement of health status in children with juvenile rheumatoid arthritis. Arthritis Rheum. 1994;37:1761–9. [2] Miyamae T, et al. Cross-cultural adaptation and validation of the Japanese version of the Childhood Health Assessment Questionnaire (CHAQ). Mod Rheumatol. 2008;18:336-43. Erratum in: Mod Rheumatol. 2008;18:344. <h3>Disclosure of Interests</h3> Takako Miyamae Speakers bureau: AbbVie, Eisai, Bristol-Meyers, Novartis, Ayumi, Taisyo-Toyama, Chugai, Yumi Tani: None declared, Takayuki Kishi: None declared, Hisashi Yamanaka Grant/research support from: AbbVie, Eisai, Bristol-Meyers, Novartis, Behringer, Astellas, Kaken, Nippon-Shinyaku, Pfizer, UCB, Ayumi, Ono, Daiichi-Sankyo, Taisyo-Toyama, Takeda, Tanabe-Mitsubishi, Chugai, Teijin Pharma, Torii, YLbio, Speakers bureau: Bristol-Meyers, Astellas, Pfizer, Daiichi-Sankyo, Takeda, Tanabe-Mitsubishi, Chugai, Teijin Pharma, YLbio, Gurkirpal Singh Shareholder of: Merck, Pfizer, Grant/research support from: Horizon, Acorda, UCB, Consultant for: Horizon, Acorda, Sancilio, Unipharm